Latest Insider Transactions at Entrada Therapeutics, Inc. (TRDA)
This section provides a real-time view of insider transactions for Entrada Therapeutics, Inc. (TRDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entrada Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entrada Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2022
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
865
-1.24%
|
$12,975
$15.06 P/Share
|
|
Sep 09
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
688
-0.31%
|
$10,320
$15.07 P/Share
|
|
Sep 08
2022
|
Nerissa Kreher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,221
-5.57%
|
$18,315
$15.13 P/Share
|
|
Sep 08
2022
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,221
+5.27%
|
$2,442
$2.1 P/Share
|
|
Sep 08
2022
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
912
-1.29%
|
$13,680
$15.15 P/Share
|
|
Sep 08
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,100
-0.5%
|
$16,500
$15.16 P/Share
|
|
Sep 01
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,503
+25.02%
|
-
|
|
Sep 01
2022
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
5,794
+3.45%
|
-
|
|
Sep 01
2022
|
Nerissa Kreher Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,172
+19.98%
|
-
|
|
Sep 01
2022
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
5,632
+7.4%
|
-
|
|
Sep 01
2022
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,125
+6.38%
|
-
|
|
Aug 31
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
171
-0.08%
|
$2,052
$12.0 P/Share
|
|
Aug 30
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
190
-0.09%
|
$2,280
$12.0 P/Share
|
|
Aug 29
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
1,639
-0.26%
|
$21,307
$13.36 P/Share
|
|
Aug 25
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,551
-12.37%
|
$21,714
$14.18 P/Share
|
|
Aug 24
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,118
-10.17%
|
$40,534
$13.88 P/Share
|
|
Aug 24
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,117
+6.66%
|
$2,234
$2.1 P/Share
|
|
Aug 23
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,909
-16.67%
|
$37,817
$13.09 P/Share
|
|
Aug 23
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,403
+7.44%
|
$2,806
$2.1 P/Share
|
|
Aug 22
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
217
-1.33%
|
$2,821
$13.0 P/Share
|
|
Aug 22
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117
+0.71%
|
$234
$2.1 P/Share
|
|
Aug 19
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,529
-34.57%
|
$110,877
$13.08 P/Share
|
|
Aug 19
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,452
+15.29%
|
$8,904
$2.1 P/Share
|
|
Aug 18
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-0.98%
|
$2,600
$13.0 P/Share
|
|
Aug 18
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.49%
|
$200
$2.1 P/Share
|
|
Aug 17
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-0.97%
|
$2,600
$13.07 P/Share
|
|
Aug 17
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.48%
|
$200
$2.1 P/Share
|
|
Aug 16
2022
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-0.97%
|
$2,600
$13.0 P/Share
|
|
Aug 16
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.48%
|
$200
$2.1 P/Share
|
|
Jul 27
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-0.95%
|
$24,000
$12.0 P/Share
|
|
Jun 27
2022
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
4,000
-1.86%
|
$48,000
$12.0 P/Share
|
|
Jun 27
2022
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
7,714
-10.62%
|
$100,282
$13.0 P/Share
|
|
Jun 06
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
38,304
+0.47%
|
$229,824
$6.39 P/Share
|
|
Jun 02
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
2,643
+0.07%
|
$13,215
$5.82 P/Share
|
|
May 24
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
23,823
+0.29%
|
$119,115
$5.84 P/Share
|
|
May 23
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
7,837
+0.19%
|
$39,185
$5.99 P/Share
|
|
May 20
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
16,849
+0.21%
|
$84,245
$5.84 P/Share
|
|
May 18
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
34,433
+0.43%
|
$172,165
$5.96 P/Share
|
|
May 17
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
18,511
+0.47%
|
$111,066
$6.13 P/Share
|
|
May 16
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
19,000
+0.49%
|
$95,000
$5.83 P/Share
|
|
Mar 01
2022
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,250
+12.35%
|
-
|
|
Mar 01
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,006
+34.89%
|
-
|
|
Mar 01
2022
|
Nerissa Kreher Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,344
+39.96%
|
-
|
|
Mar 01
2022
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
11,588
+6.9%
|
-
|
|
Mar 01
2022
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
11,263
+13.43%
|
-
|
|
Jan 13
2022
|
Dipal Doshi CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.14%
|
$10,000
$1.74 P/Share
|
|
Jan 12
2022
|
John F Crowley Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$45,000
$9.71 P/Share
|
|
Dec 29
2021
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+50.0%
|
$10,400
$2.1 P/Share
|
|
Nov 02
2021
|
Kush Parmar Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+18.09%
|
$5,000,000
$20.0 P/Share
|
|
Nov 02
2021
|
Kush Parmar Director |
BUY
Conversion of derivative security
|
Indirect |
3,827,224
+32.12%
|
-
|